title: Comparison of seroprevalences of human herpesvirus-6 and -7 in healthy blood donors from nine countries.
abstract: OBJECTIVE
  The purpose of the study was to register antibody prevalences of HHV-7 in various locations of the world in comparison to the closely related HHV-6.
  
  
  METHODS
  Sera of healthy blood donors from nine countries in five continents were titered by indirect immunofluorescent assays using HHV-6 infected HSB2 and HHV-7 infected SupT1 cells.
  
  
  RESULTS
  Antibody prevalence for HHV-7 is high (75-98%) in practically all countries except for Northern Japan (44%), with no simple correlation to elevated HHV-6 antibody titers. There were regions of low, intermediate and high mean antibody titers against HHV-7 such as 78.5-91.3 for Belgium, Israel, Japan, USA and Australia, 175.4-182.6 for Mexico and Cologne/Germany, and 389.2 for South Africa for which geographic characteristics may be responsible.
  
  
  CONCLUSIONS
  HHV-7, similar to HHV-6, is a widespread human herpesvirus with elevated antibody titers in the healthy human population essentially everywhere. The data warrant further studies to evaluate its possible pathologic potential, preferentially in persons with defective immune responses.
authors.affiliation: Immunopathology Laboratory, University of Cologne, Germany. ak104@rsl.rrz.uni-koeln.de
authors.forename: G R
authors.initials: GR
authors.lastname: Krueger
authors.forename: B
authors.initials: B
authors.lastname: Koch
authors.forename: N
authors.initials: N
authors.lastname: Leyssens
authors.forename: Z
authors.initials: Z
authors.lastname: Berneman
authors.forename: J
authors.initials: J
authors.lastname: Rojo
authors.forename: C
authors.initials: C
authors.lastname: Horwitz
authors.forename: T
authors.initials: T
authors.lastname: Sloots
authors.forename: M
authors.initials: M
authors.lastname: Margalith
authors.forename: J D
authors.initials: JD
authors.lastname: Conradie
authors.forename: S
authors.initials: S
authors.lastname: Imai
authors.forename: I
authors.initials: I
authors.lastname: Urasinski
authors.forename: M
authors.initials: M
authors.lastname: de Bruyère
authors.forename: V
authors.initials: V
authors.lastname: Ferrer Argote
authors.forename: J
authors.initials: J
authors.lastname: Krueger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood*; D001315:Australia / Q000453:epidemiology; D001530:Belgium / Q000453:epidemiology; D001782:Blood Donors; D005260:Female; D005858:Germany / Q000453:epidemiology; D006566:Herpesviridae Infections / Q000453:epidemiology* / Q000821:virology; D015654:Herpesvirus 6, Human / Q000276:immunology*; D016199:Herpesvirus 7, Human / Q000276:immunology*; D006801:Humans; D007231:Infant, Newborn; D007557:Israel / Q000453:epidemiology; D007564:Japan / Q000453:epidemiology; D008297:Male; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D011044:Poland / Q000453:epidemiology; D016036:Seroepidemiologic Studies; D013019:South Africa / Q000453:epidemiology; D014481:United States / Q000453:epidemiology
chemical_list: D000914:Antibodies, Viral